−11.56USD
−16.337MUSD
751.449K
About Ampio Pharmaceuticals, Inc.
Sector
CEO
Michael A. Martino
Headquarters
Englewood
Website
Employees (FY)
13
Founded
2008
ISIN
US03209T3077
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.
Long on AMPEAmpio Pharmaceuticals exists for over 10 years now.
The science behind its leading drug is solid.
There were many trials - in none any safety concern rose.
Most promising indication is OAK and arthritis in general.
Phase-3 results are due to late September. In the last confernece management had clea
AMPE - Speculative LongAMPIO has been in the news for treatment of COVID, and most recently for 2 trials treating 2 different types of inflammatory diseases, one is kidney related and would be very important in future treatments of Kidney Disease with chronic inflammation. I believe this would be the best case scenario,
AMPE Long IdeaStimulus seems to be leaving the spotlight. Waiting to see if it starts to shift back to Covid testing and treatment. Once I see Covid penny stocks pumping, I will jump in on this and wait for the inevitable pump!
AMPE received a approval from the FDA Clinical Trial Protocol of Inhaled Ampion on Se
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
